Armodafinil

Drug Profile

Armodafinil

Alternative Names: CEP-10953; Nuvigil; R-modafinil

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cephalon
  • Developer Cephalon; Lindner Center of HOPE; Oncotherapeutics.; Teva Pharmaceutical Industries
  • Class Acetamides; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Biogenic amine receptor agonists; Catecholamine receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia
  • Phase III Eating disorders; Fatigue
  • Discontinued Bipolar depression; Schizophrenia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jun 2016 First generic equivalent launched in USA for Hypersomnia (Tablets, 50mg, 150mg and 250mg)
  • 01 Dec 2015 Teva Pharmaceutical Industries completes a phase I trial in Hypersomnia (In children, In adolescents) in USA and Finland (NCT01624480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top